临床数据-话题@MedSci

#临床数据#

91篇内容 | 2703人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=NAT BME:使用开放性肺炎患者临床数据资源，通过深度学习预测COVID-19预后, objectType=article, longId=204965, objectId=122a204965d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122a204965d8, replyNumber=0, likeNumber=87, createdTime=2021-09-13, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122a204965d8, moduleTitle=NAT BME:使用开放性肺炎患者临床数据资源，通过深度学习预测COVID-19预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122a204965d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016756, encodeId=a46b2016e5697, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗, objectType=article, longId=204239, objectId=c17020423988, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c17020423988, replyNumber=0, likeNumber=69, createdTime=2021-04-13, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c17020423988, moduleTitle=金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c17020423988)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016744, encodeId=410b2016e44ae, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=8866例新冠肺患者临床数据分析！60岁以上男性重症患者相对预后不良！, objectType=article, longId=188062, objectId=c30c1880622e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c30c1880622e, replyNumber=0, likeNumber=50, createdTime=2020-06-04, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c30c1880622e, moduleTitle=8866例新冠肺患者临床数据分析！60岁以上男性重症患者相对预后不良！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c30c1880622e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016753, encodeId=0fa02016e537b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓, objectType=article, longId=202383, objectId=969620238316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969620238316, replyNumber=0, likeNumber=59, createdTime=2021-09-20, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969620238316, moduleTitle=IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969620238316)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016758, encodeId=2bdf2016e582c, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=抗体“鸡尾酒”疗法治疗COVID-19住院患者：已取得积极临床数据, objectType=article, longId=205032, objectId=4363205032b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4363205032b3, replyNumber=0, likeNumber=67, createdTime=2021-09-07, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4363205032b3, moduleTitle=抗体“鸡尾酒”疗法治疗COVID-19住院患者：已取得积极临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4363205032b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016743, encodeId=76092016e4383, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=110, createdTime=2020-02-12, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016750, encodeId=05d22016e509f, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=TCGA癌症临床数据资源全面介绍---癌症研究领域的全谱！, objectType=article, longId=199537, objectId=f73219953ee3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f73219953ee3, replyNumber=0, likeNumber=77, createdTime=2021-07-10, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f73219953ee3, moduleTitle=TCGA癌症临床数据资源全面介绍---癌症研究领域的全谱！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f73219953ee3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016749, encodeId=98ec2016e4965, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=61, createdTime=2021-03-23, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016747, encodeId=46d42016e47e7, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=收藏：常用医学公共数据库（含临床数据库，生信数据库和机器学习数据库）, objectType=article, longId=195880, objectId=fd511958806a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd511958806a, replyNumber=0, likeNumber=90, createdTime=2020-10-01, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd511958806a, moduleTitle=收藏：常用医学公共数据库（含临床数据库，生信数据库和机器学习数据库）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd511958806a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016740, encodeId=a0a22016e4067, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年ESMO亚洲大会：百济神州发表有关Tislelizumab的临床数据, objectType=article, longId=183564, objectId=85811835640f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85811835640f, replyNumber=0, likeNumber=94, createdTime=2020-06-03, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85811835640f, moduleTitle=2019年ESMO亚洲大会：百济神州发表有关Tislelizumab的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85811835640f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016748, encodeId=e0872016e4873, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, objectType=article, longId=197670, objectId=9e0019e6706c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e0019e6706c, replyNumber=0, likeNumber=121, createdTime=2020-08-31, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e0019e6706c, moduleTitle=NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e0019e6706c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016739, encodeId=264f2016e3957, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, objectType=article, longId=183160, objectId=386c183160e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c183160e6, replyNumber=0, likeNumber=83, createdTime=2020-06-15, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c183160e6, moduleTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c183160e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016742, encodeId=55512016e4253, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, objectType=article, longId=186734, objectId=0fc9186e3483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fc9186e3483, replyNumber=0, likeNumber=70, createdTime=2020-02-04, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fc9186e3483, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fc9186e3483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016741, encodeId=f6fd2016e4102, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, objectType=article, longId=183565, objectId=c2ab183565aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ab183565aa, replyNumber=0, likeNumber=67, createdTime=2020-10-21, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ab183565aa, moduleTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ab183565aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016728, encodeId=b03f2016e2817, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, objectType=article, longId=165949, objectId=e85d1659491a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85d1659491a, replyNumber=0, likeNumber=60, createdTime=2020-01-22, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85d1659491a, moduleTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85d1659491a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016731, encodeId=724c2016e31b3, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, objectType=article, longId=166545, objectId=dc1716654548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc1716654548, replyNumber=0, likeNumber=90, createdTime=2019-08-03, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc1716654548, moduleTitle=2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc1716654548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016730, encodeId=4b702016e309f, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=新型水凝胶GS500治疗慢性便秘的全新临床数据, objectType=article, longId=166543, objectId=d31f166543f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31f166543f3, replyNumber=0, likeNumber=75, createdTime=2020-03-04, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31f166543f3, moduleTitle=新型水凝胶GS500治疗慢性便秘的全新临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31f166543f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016737, encodeId=b6082016e37ec, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, objectType=article, longId=179536, objectId=b7571e9536db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7571e9536db, replyNumber=0, likeNumber=74, createdTime=2020-02-09, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7571e9536db, moduleTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7571e9536db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016725, encodeId=2da82016e2504, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, objectType=article, longId=163805, objectId=7958163805a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7958163805a9, replyNumber=0, likeNumber=81, createdTime=2020-01-02, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7958163805a9, moduleTitle=2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7958163805a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016732, encodeId=f6d82016e321b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, objectType=article, longId=167543, objectId=1bb016e5435e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bb016e5435e, replyNumber=0, likeNumber=127, createdTime=2020-01-04, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bb016e5435e, moduleTitle=2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bb016e5435e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

临床数据

2020-05-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

NAT BME:使用开放性肺炎患者临床数据资源，通过深度学习预测COVID-19预后

2021-09-13

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

金斯瑞子公司传奇再次公布CAR-T临床数据，总缓解率达97%，研究者期待用于更前线治疗

2021-04-13

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

8866例新冠肺患者临床数据分析！60岁以上男性重症患者相对预后不良！

2020-06-04

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

IDWeek 2020：肺炎链球菌疫苗ASP3772的I期临床数据，即将揭晓

2021-09-20

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

抗体“鸡尾酒”疗法治疗COVID-19住院患者：已取得积极临床数据

2021-09-07

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-12

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

TCGA癌症临床数据资源全面介绍---癌症研究领域的全谱！

2021-07-10

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2021-03-23

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

收藏：常用医学公共数据库（含临床数据库，生信数据库和机器学习数据库）

2020-10-01

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年ESMO亚洲大会：百济神州发表有关Tislelizumab的临床数据

2020-06-03

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

NEJM：mRNA-1273新冠疫苗I期临床数据正式发表！本月底将启动III期临床试验

2020-08-31

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据

2020-06-15

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据

2020-02-04

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据

2020-10-21

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据

2020-01-22

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年美国精神病学协会年会：pimavanserin辅助治疗重度抑郁症的II期临床数据

2019-08-03

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

新型水凝胶GS500治疗慢性便秘的全新临床数据

2020-03-04

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露

2020-02-09

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年遗传代谢紊乱学会年会：Pegzilarginase治疗精氨酸酶基因缺失患者的阳性I/II期临床数据

2020-01-02

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019 ASCO：Nektar Therapeutics公布其IL-2激动剂Bempeg与Nivolumab联用的临床数据

2020-01-04

科室
- - 订阅+
  - 更多科室
工具
服务